These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23697493)

  • 21. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 22. Indian generics companies go on spending spree.
    Jayaraman KS
    Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583
    [No Abstract]   [Full Text] [Related]  

  • 23. Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety charges.
    Kay M
    BMJ; 2013 May; 346():f3536. PubMed ID: 23723460
    [No Abstract]   [Full Text] [Related]  

  • 24. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 25. A report from CPhI Worldwide 2013, Fifth Annual Pre-Connect Conference (October 22-24, 2013 - Frankfurt, Germany).
    Kuhrt K; Gilpatrick J
    Drugs Today (Barc); 2013 Nov; 49(11):745-50. PubMed ID: 24308020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indian biogenerics industry emerges.
    Jayaraman KS
    Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract]   [Full Text] [Related]  

  • 27. Africa could learn from India's burgeoning pharma sector.
    Selvaraj S
    BMJ; 2013 Aug; 347():f4235. PubMed ID: 23913693
    [No Abstract]   [Full Text] [Related]  

  • 28. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug deal.
    Rosenberg D
    Newsweek; 2002 Aug; 140(7):64-5. PubMed ID: 12195926
    [No Abstract]   [Full Text] [Related]  

  • 30. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE; Ray CJ
    Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expert views: what the next Indian government should do for health and healthcare.
    D'Silva J
    BMJ; 2014 Apr; 348():g2479. PubMed ID: 24699174
    [No Abstract]   [Full Text] [Related]  

  • 32. [Parallel import of drugs].
    Rygnestad T; Fredriksen G; Spigset O
    Tidsskr Nor Laegeforen; 1999 Apr; 119(11):1573. PubMed ID: 10385794
    [No Abstract]   [Full Text] [Related]  

  • 33. Obama is urged to support India in supplying world with generic drugs.
    Bagcchi S
    BMJ; 2015 Feb; 350():h866. PubMed ID: 25701015
    [No Abstract]   [Full Text] [Related]  

  • 34. [Troubling shortage of drugs].
    Kiefer B
    Rev Med Suisse; 2012 May; 8(342):1144. PubMed ID: 22734188
    [No Abstract]   [Full Text] [Related]  

  • 35. The crisis in access to essential medicines in India: key issues which call for action.
    Bhargava A; Kalantri SP
    Indian J Med Ethics; 2013; 10(2):86-95. PubMed ID: 23697486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharma Dynamics: targeting safe, effective and affordable medication for South Africa and neighbouring countries.
    Cardiovasc J Afr; 2009; 20(1):85. PubMed ID: 19287824
    [No Abstract]   [Full Text] [Related]  

  • 37. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 38. Lead Essay: Money, Equity and Access to Medicines.
    Ghinea N; Lipworth W; Kerridge I
    J Bioeth Inq; 2020 Mar; 17(1):25-27. PubMed ID: 32124176
    [No Abstract]   [Full Text] [Related]  

  • 39. Fine print TRIPS up multinational and Indian companies.
    Frantz S
    Nat Rev Drug Discov; 2005 Feb; 4(2):94-5. PubMed ID: 15759327
    [No Abstract]   [Full Text] [Related]  

  • 40. Competition watchdog finds new target: overpriced generics.
    Hawkes N
    BMJ; 2016 Dec; 355():i6712. PubMed ID: 27974337
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.